Risk of SARS-CoV-2 reinfection after natural infection

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

(2021) Catherine J. Reynolds et al.   Science Immunology

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

(2021) Charlotte Manisty et al.   LANCET

Immunity to SARS-CoV-2 variants of concern

(2021) Daniel M. Altmann et al.   SCIENCE

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection

(2021) Charlotte Manisty et al.   EBioMedicine

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

(2021) Christian Holm Hansen et al.   LANCET

Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

(2020) Annsea Park et al.   Cell Host & Microbe

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

(2020) Kelvin Kai-Wang To et al.   CLINICAL INFECTIOUS DISEASES

Seasonal coronavirus protective immunity is short-lasting

(2020) Arthur W. D. Edridge et al.   NATURE MEDICINE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting

(2020) Laith J Abu-Raddad et al.   CLINICAL INFECTIOUS DISEASES